KRAS inhibition in consequence leads to an increased sensitivity of tumor cells to type I and II IFNs, which translates to higher expression of IFN-induced genes such as T cell chemoattractants and antigen presentation genes that could positively affect antitumor immunity in vivo. The gene discussed is IFNA1; the disease is neoplasm.